Nanoneedle

Global Market Report for Zinc Oxide Nanoparticles 2023-2033, Featuring Profiles of 25+ Companies Including Altana Chemie, BASF, Symrise, Tata Chemicals and Tayca Corporation - ResearchAndMarkets.com

Retrieved on: 
Friday, June 23, 2023
Technology, Nanotechnology, Natural Resources, Mining, Minerals, Nanorod, Nanoparticle, Zinc oxide, Nanowire, Powder, Nano, UVA, Carbon, Cosmetics, Research, Nanostructure, UVB, Nanoneedle, Nanoc, UV, Textile, Maharashtra University of Health Sciences, Environmental remediation

The "Global Market for Zinc Oxide Nanoparticles 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Zinc Oxide Nanoparticles 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The market for zinc oxide nanoparticles (Nano-ZnO) is mainly driven by the demand for UVA/B filters in sunscreens and sun protection cosmetics.
  • By means of different fabrication conditions, zinc oxide can be moulded into nanostructures, nanowires, nanotubes, nanorods, nanoribbons, nanoneedles, nanocables etc.
  • 26 Company profiles of zinc oxide nanoparticles producers including products, applications and contact details.

NanoMosaic To Develop Novel Capture Methodologies as Dr. Abhishek Chatterjee Joins NanoMosaic Scientific Advisory Board

Retrieved on: 
Tuesday, January 24, 2023
Doctor of Philosophy, Boston College, Proteomics, Entrepreneurship, Dicarboxylic acid, CSO, Partnership, SAB, Virology, Protein, Physician, United States Air Force Scientific Advisory Board, Genetic code, Antibody, Nanoneedle, Research, Synthetic biology, Pharmaceutical industry, Vaccine, Chemistry

Abhishek Chatterjee, Ph.D. joins NanoMosaic SAB.

Key Points: 
  • Abhishek Chatterjee, Ph.D. joins NanoMosaic SAB.
  • Dr. Chatterjee has developed various novel genetic code expansion tools to allow site-specific incorporation of enabling noncanonical amino acids into proteins in vivo.
  • Dr. Chatterjee is also co-founder, senior advisor and Chair of Scientific Advisory Board of BrickBio Inc.
    "NanoMosaic's powerful MosaicNeedle™ technology has the potential to revolutionize the world of protein detection and quantification.
  • The novel antibody has been designed to have higher affinities and enhanced performance on NanoMosaic Tessie™ platform.

NanoMosaic Wins the Prestigious NEVY Award (New England Venture Capital) for Emerging MedTech Company of the Year

Retrieved on: 
Tuesday, December 13, 2022
Winter Street Concourse, New England Venture Capital Association, Plasma, House, House of Blues, Health, Entrepreneurship, Research, Nanoneedle, Proteome, Proteomics, Foot, Pharmaceutical industry, Tessie

BOSTON, Dec. 13, 2022 /PRNewswire/ -- NanoMosaic, the leader in next-generation digital proteomic interrogation technology, won the prestigious NEVY, New England Venture Capital award, for, "Emerging MedTech Company of the Year."

Key Points: 
  • BOSTON, Dec. 13, 2022 /PRNewswire/ -- NanoMosaic, the leader in next-generation digital proteomic interrogation technology, won the prestigious NEVY, New England Venture Capital award, for, "Emerging MedTech Company of the Year."
  • The award was presented to NanoMosaic at the sold-out awards ceremony at the House of Blues in Boston on December 8, 2022.
  • "We are honored and thrilled to receive this prestigious award from such a well-respected group as The New England Venture Capital Association - thank you NEVYs!," Boyce continued.
  • The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.

Dr. George Green Joins NanoMosaic Scientific Advisory Board

Retrieved on: 
Wednesday, November 9, 2022
Proteomics, Industry, Patient, Biomarker, Precision medicine, SRL Diagnostics, Bristol Myers Squibb, Entrepreneurship, Nanoneedle, SAB, BMS, CSO, Head, Research, CEO, Pharmaceutical industry, Medical device, Fine chemical, Tessie

BOSTON, Nov. 9, 2022 /PRNewswire/ -- NanoMosaic, the pioneer and leader of nanoneedle technology (MosaicNeedle) for proteomics and multiomics, announced the establishment of the NanoMosaic Scientific Advisory Board (SAB) to support the company's vision to bring their nanoneedle-powered digital proteomic platform to the life science research and diagnostic community.

Key Points: 
  • BOSTON, Nov. 9, 2022 /PRNewswire/ -- NanoMosaic, the pioneer and leader of nanoneedle technology (MosaicNeedle) for proteomics and multiomics, announced the establishment of the NanoMosaic Scientific Advisory Board (SAB) to support the company's vision to bring their nanoneedle-powered digital proteomic platform to the life science research and diagnostic community.
  • NanoMosaic is pleased to announce that George A.
  • Green IV is world-renowned expert and leader in Precision Medicine and Companion Diagnostics.
  • "We are honored and thrilled to have George join the NanoMosaic Scientific Advisory Board," Boyce concluded.

NanoMosaic: John Boyce To Continue to Build Tiger Gene, Remain as Executive Chairman of the Board, and Hire a Full-Time CEO

Retrieved on: 
Thursday, October 20, 2022
Proteomics, Therapy, Growth, Genomics, Research, Multimedia, Executive, Technology, Initial public offering, Drug discovery, Board, CEO, Tiger Management, Interim, Nanoneedle, Management, Fine chemical, Tessie

John will remain as the Executive Chairman of the Board.

Key Points: 
  • John will remain as the Executive Chairman of the Board.
  • "NanoMosaic is on an extremely exciting trajectory in terms of the broad capabilities of its technology, its strong research and development teams, as well as its regulatory and commercial teams," stated John Boyce, Co-Founder of Tiger Gene, Co-Founder and Interim CEO of NanoMosaic, as well as Executive Chairman of NanoMosaic.
  • The company has retained a top tier executive search firm to conduct the search and is actively interviewing candidates.
  • The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content.

NanoMosaic Expands Its Diagnostic Repertoire with Exclusive Rights to Novel Clinical Biomarker Test

Retrieved on: 
Wednesday, October 12, 2022
Proteomics, Surgery, Hospital, Diagnosis, Patient, Massachusetts General Hospital, Entrepreneurship, Harvard Medical School, CEO, Corporate development, Prognosis, Alzheimer's disease, Warner, Nanoneedle, Delirium, FDA, Pharmaceutical industry, Tessie, Anesthesia

BOSTON, Oct. 12, 2022 /PRNewswire/ -- NanoMosaic, a leader in proteomics and multi-omics via its novel MosaicNeedle™ technology and Tessie™ system has expanded its diagnostic capabilities to enable better treatment options for patients.

Key Points: 
  • After successful development of a novel serum biomarker test for Post-Operative Delirium by Dr. Zhongcong Xie, Professor of Anesthesia at Massachusetts General Hospital and Harvard Medical School, using the NanoMosaic Tessie system, NanoMosaic has negotiated the exclusive right to license the biomarker test developed for diagnosis and prognosis of anesthesia-induced Delirium and Alzheimer's Disease.
  • The NanoMosaic novel nanoneedle technology has enabled Dr. Xie and his group to develop a sensitive test for better diagnosis and prognosis of patients with post-operative delirium pre and post-surgery enabling better anesthesia decisions.
  • Working closely with the FDA NanoMosaic will grant clinicians, hospitals, and clinical research organizations, access to the novel serum biomarker test to ensure, that for the first time, patients' anesthesia is informed by a biomarker based test.
  • The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.

Publication on NanoMosaic Technology in the, "British Journal of Anaesthesia"

Retrieved on: 
Tuesday, September 20, 2022
Tau, Workflow, Time, Immunoassay, L.L.C, Entrepreneurship, Biomarker, Hospital, Dementia, Delirium, Annals of Surgery, Massachusetts General Hospital, Patient, PET, Nanoneedle, CEO, Serum, Cardiopulmonary bypass, Alzheimer's disease, British Journal of Anaesthesia, Harvard Medical School, Research, Plasma, Medical imaging, Tessie

BOSTON, Sept. 20, 2022 /PRNewswire/ -- With NanoMosaic's nanoneedle technology, researchers from Massachusetts General Hospital and Harvard Medical School detected Tau and phosphor-Tau proteins in serum samples from patients under major cardiac surgery with cardiopulmonary bypass. Elevation of Tau and phosphor-Tau proteins were observed before and after the surgery, and Tau protein is identified as a potential serum biomarker of delirium after cardiac surgery. The study has been published in the British Journal of Anaesthesia.

Key Points: 
  • The study has been published in the British Journal of Anaesthesia.
  • "NanoMosaic has implemented the tools and infrastructure to transition from the research bench to the clinic," Boyce concluded.
  • The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content.
  • The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.

NANOMOSAIC APPOINTS RAAJ VENKATESAN AS CHIEF REGULATORY OFFICER

Retrieved on: 
Monday, July 25, 2022
Certified Quality Engineer, Time, University, Genomics, Medical device, RAC, Industry, Research, Bharathidasan University, Degree, Use, Health, Electrical engineering, Diagnosis, CEO, Certified Quality Auditor, BD (company), Bruker, Argus retinal prosthesis, Health Canada, Instrumentation, Engineering, Biomedical engineering, Proteomics, Technology, FDA, Ancestry.com, RAPS, Patient, Blood, Tau protein, Nanoneedle, Association, Raaj, Bio-Rad Laboratories, BD, Regulatory affairs, ASQ, Reliability engineering, Pharmaceutical industry, Quality, Electronics, Tessie, Plasma

Raaj Venkatesan brings more than 17 years of experience in regulatory affairs, regulatory compliance and quality engineering in the medical device and In Vitro Diagnostics industry.

Key Points: 
  • Raaj Venkatesan brings more than 17 years of experience in regulatory affairs, regulatory compliance and quality engineering in the medical device and In Vitro Diagnostics industry.
  • Prior to joining Nanomosaic, Raaj served as a Regulatory Affairs and Quality executive at NovaSignal Corporation, Ancestry Health, the healthcare division of AncestryDNA and Exosome Diagnostics.
  • Raaj is Regulatory Affairs Certified (RAC-US, RAC-EU) by the Regulatory Affairs Professionals Society (RAPS) and is also an ASQ Certified Manager of Quality, Reliability Engineer, Quality Auditor, Biomedical Auditor and Quality Engineer.
  • "I am honored and excited to join Nanomosaic at such an exciting time for the company and the proteomics space," said Raaj Venkatesan.

NanoMosaic Unveils a Method To Enable Proteomics By Combining Aptamers and Antibodies on its MosaicNeedle™ Platform at 2022 AACR

Retrieved on: 
Monday, April 4, 2022
Network, Multimedia, Proteomics, AACR, Proteome, American Association for Cancer Research, American Association, CEO, Poster, Aptamer, LLC, Bias, Association, Workflow, Nanoneedle, Medi-Cal Access Program, Antibody, Medical imaging, Fine chemical, Tessie

The NanoMosaic Tessieplatform leverages the power of MosaicNeedlesto provide both the sensitivity and dynamic range to interrogate the proteome in complex matrices at high throughput.

Key Points: 
  • The NanoMosaic Tessieplatform leverages the power of MosaicNeedlesto provide both the sensitivity and dynamic range to interrogate the proteome in complex matrices at high throughput.
  • The nanoneedle acts both as a capture substrate and detection probe, thereby eliminating the upfront capture steps and downstream detection reactions that may introduce bias.
  • The poster (#5391) entitled "MosaicNeedles: A tool for large-scale proteomics combining antibodies and aptamers" will be presented at AACR's "Proteomics, Signaling Networks and Biomarker Discovery" session.
  • "The MosaicNeedleplatform provides a scalable approach to enable proteomics and multi-omics, an end-to-end solution from biomarker discovery to diagnostic assay development."

NanoMosaic Announces its "Proteomics/Multi-Omics Early Access Program" and its First System Sale to a Prestigious Boston Hospital

Retrieved on: 
Wednesday, February 2, 2022
Entrepreneurship, Nanoneedle, CEO, Patient, Sale, DIY, Warner, Goal, Genomics, Technology, Proteomics, Research, Program, MA, Access, Company, CLIA, Organic acid, Business development, Medi-Cal Access Program, Antibody, Pharmaceutical industry, Tessie, Investment

The Company is making a limited number of systems available for purchase under its Early Access Program to thought leaders conducting groundbreaking research in proteomics and multi-omics.

Key Points: 
  • The Company is making a limited number of systems available for purchase under its Early Access Program to thought leaders conducting groundbreaking research in proteomics and multi-omics.
  • Under the program, NanoMosaic has announced its first system sale to a prestigious Boston, MA hospital in the Longwood area to a certified CLIA lab that is developing diagnostic applications aimed to positively impact patients' lives.
  • The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content.
  • The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics.